QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

NCT07025239 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

430

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: QL1706
DRUG: Bevacizumab
DRUG: Oxaliplatin
DRUG: Capecitabine
DRUG: Placebo

Sponsor

Qilu Pharmaceutical Co., Ltd.